As treatment with VEGFR‐TKIs in various cancer types is becoming more widespread and prolongs the survival of patients with cancer, it is necessary to organize a policy on the management of proteinuria and how to prioritize cancer treatment. The gene discussed is KDR; the disease is cancer.